Updates

Date:27August 2026 Ref.No.:TCPCL/SEC/2026-27/00040 TheGeneralManager, TheManager, Corporaterelationshipdepartment, Listingdepartment, BSELimited NationalStockExchangeofIndiaLimited PhirozeJeejeebhoyTowers, ExchangePlaza,C-1,Block-G, DalalStreet,Fort, Bandra-KurlaComplex,Bandra(E), Mumbai-400001 Mumbai-400051 ScripCode:543321 ScripSymbol:TATVA Subject: Submission of Business Responsibility and Sustainability Report of the Company for the Financial Year (“FY”) 2025-26 under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(“SEBIListingRegulations”) DearSir/Madam, Pursuant toRegulation 34(2)(f) of the SEBI Listing Regulations, we are submitting herewith the Business Responsibility and Sustainability Report (“BRSR”) for FY 2025-26 which formspartoftheAnnualReportFY2025-26. TheBRSRisalsoavailableonthewebsiteoftheCompanyatwww.tatvachintan.com. Kindlytaketheaboveinformationonrecord. Thankingyou, Yoursfaithfully, ForTatvaChintanPharmaChemLimited IshwarNayi CompanySecretaryandComplianceOfficer M.No.:A37444 Encl.:Asabove Annexure - H to the Board’s Report Business Responsibility and Sustainability Report Section A: General Disclosures I. Details of the listed entity: 1. Corporate Identity Number (CIN) of the Listed Entity L24232GJ1996PLC029894 2. Name of the Listed Entity Tatva Chintan Pharma Chem Limited 3. Year of Incorporation 1996 4. Registered Office Address Plot No. 502/17, GIDC Estate, Ankleshwar, Dist. Bharuch, Gujarat - 393002, India 5. Corporate Address Plot No. 353, Makarpura GIDC, Vadodara, Gujarat - 390010, India 6. E-mail cs@tatvachintan.com 7. Telephone +91-7574848533/34 8. Website www.tatvachintan.com 9. Financial year for which reporting is being done 01 April 2025 to 31 March 2026 10. Name of the Stock Exchange(s) where shares are listed 1. BSE Limited (BSE); and 2. National Stock Exchange of India Limited (NSE) 11. Paid-up Capital ` 233.92 Million 12. Name and contact details (telephone, email address) of the Mr. Chintan N. Shah person who may be contacted in case of any queries on the Chairman and Managing Director BRSR report Telephone number: +91 75748 48533/34 Email ID: chintan@tatvachintan.com 13. Reporting boundary - Are the disclosures under this report Standalone Basis made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). 14. Name of assurance provider Not Applicable 15. Type of assurance obtained Not Applicable II. Products / Services: 16. Details of business activities (accounting for 90% of the turnover): Description of main activity Description of business activity % of turnover of the entity Specialty Chemicals Manufacturing of specialty chemical with diverse portfolio of Structure 98.94% Directing Agents, Phase Transfer Catalysts, Electrolyte Salts and Solutions and Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals 17. Products / Services sold by the entity (accounting for 90% of the entity’s Turnover): Sr. % of total turnover Product / Service NIC Code No. contributed 1 Structure Directing Agents (SDA) 20119 40.74% 2 Phase Transfer Catalysts (PTC) 20119 23.12% 3 Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC) 20119 33.05% 4 Electrolyte Salts and Solutions (ESS) 20119 2.03% III. Operations: 18. Number of locations where plants and / or operations / offices of the entity are situated: Locations Number of plants Number of offices Total National 2 2 4 International 0 0 0 Annual Report 2025-26 1 19. Markets served by the entity: a. Number of locations: Locations Number National (no. of states) 17 International (no. of countries) 30 b. What is the contribution of exports as a percentage of the total turnover of the entity? c. A brief on types of customers: We have a wide customer base spread across major geography and across diverse sectors including: - Agro chemicals - Active pharmaceuticals ingredients - Zeolites manufactures - Chemicals / Specialty chemicals - Personal care and hygiene - Super capacitors and energy storage devices - Resins - Mining and metals industry - Specialty chemicals for semiconductor application The Company serves customers directly as well as through agents. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled) Sr. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 363 341 93.94% 22 6.06% 2. Other than Permanent (E) 0 0 0% 0 0% 3. Total employees (D + E) 363 341 93.94% 22 6.06% WORKERS 4. Permanent (F) 430 429 99.77% 1 0.23% 5. Other than Permanent (G) 304 303 99.67% 1 0.33% 6. Total workers (F + G) 734 732 99.73% 2 0.27% b. Differently abled Employees and workers: Sr. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 1 1 100% 0 0% 2. Other than Permanent (E) 0 0 0% 0 0% 3. Total differently abled employees (D + E) 1 1 100% 0 0% DIFFERENTLY ABLED WORKERS 4. Permanent (F) 1 1 100% 0 0% 5. Other than Permanent (G) 0 0 0% 0 0% 6. Total differently abled workers (F + G) 1 1 100% 0 0% 2 Tatva Chintan Pharma Chem Limited 21. Participation / Inclusion / Representation of women: Total No. and percentage of Females (A) No. (B) % (B / A) Board of Directors (BOD)* 6 1 16.67% Key Management Personnel (KMP)* 5 0 0% * M r. Chintan N. Shah, Chairman and Managing Director, Mr. Ajaykumar M. Patel, Whole-time Director and Mr. Shekhar R. Somani, Whole-time Director, are part of both BOD and KMP. 22. Turnover rate for permanent employees and workers FY 2025-26 FY 2024-25 FY 2023-24 (Turnover rate in %) (Turnover rate in %) (Turnover rate in %) Male Female Total Male Female Total Male Female Total Permanent Employees 50.52% 38.10% 49.79% 30.81% 35.71% 30.06% 24.08% 21.28% 23.96% Permanent Workers 36.77% 0% 36.72% 21.76% 0% 21.76% 15.68% 0% 15.68% V. Holding, Subsidiary and Associate Companies (Including Joint Ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures: Name of the holding / subsidiary Indicate whether holding Does the entity indicated at column A, Sr. % of shares held / associate companies / joint / subsidiary / associate / joint participate in the business responsibility No. by listed entity ventures (A) venture initiatives of the listed entity? (Yes/No) 1 Tatva Chintan USA Inc. Wholly Owned Subsidiary of 100% No the Company 2 Tatva Chintan Europe B.V. Wholly Owned Subsidiary of 100% No the Company VI. CSR Details 24. i. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes ii. Turnover (in ` ): 4,962.96 Million (FY 2025-26) iii. Net worth (in ` ): 7,582.29 Million (FY 2025-26) VII. Transparency and Disclosures Compliances 25. Complaints / Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: Grievance redressal FY 2025-26 FY 2024-25 Stakeholder mechanism in place Number of Number of Number of Number of group from whom If Yes, then provide complaints complaints complaints complaints Remarks Remarks complaint is received web-link for grievance filed during pending resolution filed during pending resolution redress policy the year at close of the year the year at close of the year Communities Yes. Please refer Note 0 0 NA 0 0 NA A1 below Investors (other Yes. Please refer Note 0 0 NA 0 0 NA than shareholders) A2 below Shareholders Yes. Please refer Note 0 0 NA 1 0 NA A3 below Employees and Yes. Please refer Note 0 0 NA 0 0 NA workers A4 below Customers Yes. Please refer Note 14 0 NA 10 0 NA A5 below Value Chain Yes. Please refer Note 0 0 NA 0 0 NA Partners A6 below Other (please Not Applicable specify) Annual Report 2025-26 3 Notes: A1: At all our manufacturing locations, we ensure that there is regular engagement on a pro-active basis with the local communities and t [Showing first 8,000 characters — download PDF for full document]